As a scientifically oriented and impactful full-service clinical research organization (CRO) that is committed to partnering with pharmaceutical, biotechnology, and medical device firms to advance their therapies throughout the entire clinical development and regulatory submission process, Veristat works each day with a focus on improving the lives of patients with rare cancers.
January 10, 2018
CYCLE FOR SURVIVAL 2018
Every dollar represents hope, strength, and a lasting impact!
November 17, 2017
A Recap of the New York Medidata NEXT Event: Where Science Meets Technology Meets the Future
Kathleen Boruchowski, Associate Director of Data Management, attended the Medidata NEXTconference in New York City on November 8-10. The conference, which has many global locations throughout the year, offered Medidata’s customers a front row seat to learn how data, insights, and technology are transforming the clinical trials industry and ultimately accelerating the hope for patients desperately seeking new treatment options.
November 8, 2017
Veristat Hosts Its 2017 Annual International Company Meeting
Last week, Veristat gathered nearly 200 team members from multiple countries for our annual International Company Meeting. What better a place to host our team meeting than Gillette Stadium, home to the five-time Superbowl championship winning New England Patriots.
October 18, 2017
Explore What We Learned at the 8th Clinical Quality Oversight Forum
Veristat’s Senior Director of Corporate Compliance attended the 8th Clinical Quality Oversight Forum, an annual conference which took place 10-13 October 2017 in Philadelphia, PA.
August 3, 2017
Last week, Veristat attended the Massachusetts Biotechnology Council (MassBio) forum titled “Evolution of an Academic Discovery: First Person Account of the Development of Velcade®”.
December 15, 2016
Read more about this and the discussions that you missed at the MassBio Forum on Adaptive Designs in Clinical Research that took place last month.
Just last week, in the midst of the daily chaos of building new clinical trial databases, working on impending regulatory submissions, holding project team meetings, and programing tables figures & listings, Veristat paused its operations for one day in order to reflect upon and celebrate its contributions to drug development.
At the 2016 Duke Industry Statistics Symposium, Dr. Robin Bliss, in collaboration with Dr. Jing Wang of Gilead Sciences, lead a discussion on “Biomarker-Driven Clinical Trial Designs for Precision Medicine.” Dr. Bliss highlighted two Adaptive Enrichment Clinical Trials performed by Veristat as case studies for how to select and execute an enrichment clinical trial design.